Ai F, Wang N, Zhang X, Sun T, Zhu Q, Kong W, Wang F, Zhu G (2018) An upconversion nanoplatform with extracellular pH-driven tumor-targeting ability for improved photodynamic therapy. Nanoscale 3:380. https://doi.org/10.1039/c7nr06874c

Article  CAS  Google Scholar 

Andreev OA, Engelman DM, Reshetnyak YK (2014) Targeting diseased tissues by pHLIP insertion at low cell surface pH. Front Oncol 5:97. https://doi.org/10.3389/fphys.2014.00097

Article  Google Scholar 

Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H (2008) Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10(6):625–632. https://doi.org/10.1080/14653240802301872

Article  PubMed  CAS  Google Scholar 

Bao X, Xu L, Lu X, Jia L (2016) Optimization of dilution refolding conditions for a camelid single domain antibody against human beta-2-microglobulin. Protein Exp Purif 117:59–66. https://doi.org/10.1016/j.pep.2015.09.019

Article  CAS  Google Scholar 

Behar G, Siberil S, Groulet A, Chames P, Pugniere M, Boix C, Sautes-Fridman C, Teillaud J, Baty D (2008) Isolation and characterization of anti-Fc RIII (CD16) Llama single-domain antibodies that activate natural killer cells. Protein Eng Sel 21(1):1–10. https://doi.org/10.1093/protein/gzm064

Article  CAS  Google Scholar 

Behar G, Chames P, Teulon I, Cornillon A, Alshoukr F, Roquet F, Pugnière M, Teillaud JL, Gruaz-Guyon A, Pèlegrin A, Baty D (2009) Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J 276(14):3881–3893. https://doi.org/10.1111/j.1742-4658.2009.07101.x

Article  PubMed  CAS  Google Scholar 

Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou J-Z, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL (2017) Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy 19(10):1225–1232. https://doi.org/10.1016/j.jcyt.2017.07.008

Article  PubMed  CAS  Google Scholar 

Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107(1):159–166. https://doi.org/10.1182/blood-2005-04-1351

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bryceson YT, Ljunggren HG, Long EO (2009) Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 114(13):2657–2666. https://doi.org/10.1182/blood-2009-01-201632

Article  PubMed  PubMed Central  CAS  Google Scholar 

Burkhardt JK, Hester S, Lapham CK, Argon Y (1990) The lytic granules of natural killer cells are dual-function organelles combining secretory and pre-lysosomal compartments. J Cell Biol 111(6 Pt 1):2327–2340. https://doi.org/10.1083/jcb.111.6.2327

Article  PubMed  CAS  Google Scholar 

Burns KE, Robinson MK, Thévenin D (2015) Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP–monomethyl Auristatin E Conjugates. Mol Pharm 12(4):1250–1258. https://doi.org/10.1021/mp500779k

Article  PubMed  PubMed Central  CAS  Google Scholar 

Burns KE, Hensley H, Robinson MK, Thévenin D (2017) Therapeutic efficacy of a family of pHLIP-MMAF conjugates in cancer cells and mouse models. Mol Pharm 14(2):415–422. https://doi.org/10.1021/acs.molpharmaceut.6b00847

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ (2015) MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518(7537):107–110. https://doi.org/10.1038/nature13905

Article  PubMed  CAS  Google Scholar 

Cortez-Retamozo V, Lauwereys M, Hassanzadeh GH, Gobert M, Conrath K, Muyldermans S, De Baetselier P, Revets H (2002) Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 98(3):456–462. https://doi.org/10.1002/ijc.10212

Article  PubMed  CAS  Google Scholar 

Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15(2):81–94. https://doi.org/10.1038/nrclinonc.2017.166

Article  PubMed  CAS  Google Scholar 

Dharmaratne NU, Kaplan AR, Glazer PM (2021) Targeting the hypoxic and acidic tumor microenvironment with pH-sensitive peptides. Cells 10(3):541. https://doi.org/10.3390/cells10030541

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dumoulin M, Conrath K, Meirhaeghe AV, Meersman F, Heremans K, Frenken LGJ, Muyldermans S, Wyns L, Matagne A (2002) Single-domain antibody fragments with high conformational stability. Protein Sci 11:500–515. https://doi.org/10.1110/ps.34602

Article  PubMed  PubMed Central  CAS  Google Scholar 

DuPont M, Visca H, Moshnikova A, Engelman DM, Reshetnyak YK, Andreev OA (2023) Tumor treatment by pHLIP-targeted antigen delivery. Front Bioeng Biotechnol. https://doi.org/10.3389/fbioe.2022.1082290

Article  PubMed  PubMed Central  Google Scholar 

Ernst D, Williams BA, Wang XH, Yoon N, Kim KP, Chiu J, Luo ZJ, Hermans KG, Krueger J, Keating A (2019) Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of hodgkin lymphoma targets via ARF6/PLD-1. Blood Cancer J 9(2):6. https://doi.org/10.1038/s41408-018-0168-2

Article  PubMed  PubMed Central  Google Scholar 

Fan K, Jiang B, Guan Z, He J, Yang D, Xie N, Nie G, Xie C, Yan X (2018) Fenobody: a ferritin-displayed nanobody with high apparent affinity and half-life extension. Anal Chem 90(9):5671–5677. https://doi.org/10.1021/acs.analchem.7b05217

Article  PubMed  CAS  Google Scholar 

Frenken LGJ, van der Linden RHJ, Hermans PWJJ, Bos JW, Ruuls RC, de Geus B, Verrips CT (2000) Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces Cerevisiae. J Biotechnol 78(1):11–21. https://doi.org/10.1016/S0168-1656(99)00228-X

Article  PubMed  CAS  Google Scholar 

Friedman J, Padget M, Lee J, Schlom J, Hodge J, Allen C (2019) Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. Oral Oncol 90:38–44. https://doi.org/10.1016/j.oraloncology.2019.01.017

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891–899. https://doi.org/10.1038/nrc1478

Article  PubMed  CAS  Google Scholar 

Giles AJ, Hao S, Padget M, Song H, Zhang W, Lynes J, Sanchez V, Liu Y, Jung J, Cao X, Fujii R, Jensen R, Gillespie D, Schlom J, Gilbert MR, Nduom EK, Yang C, Lee JH, Soon-Shiong P, Hodge JW, Park DM (2019) Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. JCI Insight 4(20):e130688. https://doi.org/10.1172/jci.insight.130688

Article  PubMed  PubMed Central  Google Scholar 

Gogia P, Ashraf H, Bhasin S, Xu Y (2023) Antibody-drug conjugates: a review of approved drugs and their clinical level of evidence. Cancers 15:1–32. https://doi.org/10.3390/cancers15153886

Article  CAS  Google Scholar 

Golijanin J, Amin A, Moshnikova A, Brito JM, Tran TY, Adochite R-C, Andreev GO, Crawford T, Engelman DM, Andreev OA, Reshetnyak YK, Golijanin D (2016) Targeted imaging of urothelium carcinoma in human bladders by an ICG pHLIP peptide ex vivo. Proc Natl Acad Sci USA 113(42):11829–11834. https://doi.org/10.1073/pnas.1610472113

Article  PubMed  PubMed Central  CAS  Google Scholar 

Huang C, Li D, Ren J, Ji F, Jia L (2019) Generation and application of fluorescent anti-human Β2-microglobulin VHHs via amino modification. Molecules 24(14):2600. https://doi.org/10.3390/molecules24142600